Left ventricular (LV) remodeling is a summation of cellular and extracellular matrix (ECM) events, which invariably occur following a myocardial infarction (MI), and is an important predictor of clinical outcomes. Increased induction of the ECM proteolytic enzymes, the matrix metalloproteinases (MMPs) occur in the early and late phases of post-MI remodeling. While MMP inhibition remains an important therapeutic target in the context of post-MI remodeling, systemic delivery of broad spectrum pharmacologic MMP inhibitors can be associated with adverse events, and these concerns coupled with difficulties in dosing regimens, have hindered clinical progress. We have successfully moved the field forward in terms of demonstrating that localized delivery of a hyaluronic acid based hydrogel (HA-gel) and release of an MMP inhibitory peptide could effectively attenuate adverse post-MI remodeling. We now propose to further advance the translational and clinical relevance of these proof of concept studies and “repurpose” MMP inhibitors that were advanced clinically by overcoming past obstacles regarding systemic delivery and specificity. Our guiding hypothesis is that using an MMP sensitive HA-gel, which will release a pharmacological MMP inhibitor selectively into the MI region, in stochastic response to MMP activity, will effectively and favorably alter the course of adverse post-MI remodeling. We will advance the translational relevance of these studies by demonstrating the beneficial effects of the HA-gel/MMP inhibitor construct using novel delivery methods. These studies will provide the pivotal pre-clinical information in order to further advance the therapeutic avenue of localized MMP inhibitory control in order to interrupt the inexorable progression of adverse LV remodeling post-MI and subsequent heart failure.
• Eckhouse SR, Purcell BP, Oelsen JM, Logdon CB, Rawls WF, Patel RK, Zellars KN, Stroud RE, Jones JA, Mukherjee R, Gorman JH III, Gorman RC, Black RA, Burdick JA, Spinale FG. Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med. 2014 Feb 12;6(223):223ra21. PMCID: PMC4365799
• Purcell BP, Lobb DC, Charati MB, Dorsey SM, Wade RJ, Zellars KN, Doviak H, Pettaway S, Logdon CB, Shuman JA, Freels PD, Gorman JH, Gorman RC, Spinale FG, Burdick JA. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater. 2014 Mar 30 Epub. 2014 Jun;13(6):653-61. PMCID: PMC4031269
• Villarreal F, Spinale FG. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014 Jul 1;90(1):7-15. PMCID: PMC4060262